Gland Pharma partners with Neuland Labs for sterile API manufacturing

Marquee Jv AnnouncedStrategic Transactions View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹2552.00

prior close

₹2570.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%+1.3% vs market

Pharmaceuticals peers, median of 167sector-0.2%+1.7% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Smallcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.9

15m

+0.8

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.2+1.3-0.2+1.7

Next day

+1.2+0.2+1.0+0.3+0.8

+4.6+0.1+4.5+0.6+4.0

+14.6+0.3+14.3+0.6+14.0

+12.9+0.1+12.8+0.5+12.3

+16.2+0.2+15.9+0.9+15.3

+13.7-0.1+13.8-0.2+13.9

15d

+12.7+0.6+12.1-0.2+12.9

+16.5+0.9+15.6+2.3+14.2

+17.8-2.3+20.1+2.4+15.4

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gland Pharma and Neuland Laboratories announce a long-term strategic CDMO partnership. Gland will build a new cGMP sterile manufacturing suite at its Visakhapatnam JNPC facility for sterile APIs used in microparticle depot products. The suite adds about 1400 kg annual capacity, meeting USFDA and EU standards. Partnership combines Neuland's complex API development with Gland's sterile manufacturing expertise for global markets.

Likely market impact

Strengthens Gland's CDMO capabilities and revenue potential in sterile injectables. Positive for long-term growth.